Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) ('Alpha Tau”), the developer of the innovative alpha-radiation cancer therapy ...
Pancreatic cancer multi-center clinical trial in U.S. is underway; patient recruitment expected to be completed by the end of Q1 2026 ...
- Final results from first pancreatic cancer study in Montreal demonstrate 81% disease control rate, or 87% excluding the first two patients - - Immune markers demonstrate immune system preservation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results